$DYAI

Dyadic International (DYAI) reported Q2 2026 progress, with an 80% productivity increase in its animal-free recombinant human transferrin program, reducing costs by 40%. The company saw product advancements across life sciences, food, and bioindustrial sectors, including initial sales and partnerships. Dyadic's strategy focuses on leveraging improvements to support customer qualification and strategic collaborations.

Dyadic (DYAI) reported $4.7M cash and short-term securities at June 30, 2026, down from $8.6M at end-2025, with $3.8M cash burn in the first half of 2026. After its Q2 report, it announced a $2.9M registered direct offering and private placement, expecting $2.28M net proceeds, plus an ATM with Craig-Hallum. The company also updated multiple partnerships and noted going-concern doubt.

Dyadic International said it raised about $2.9 million via a registered direct offering and a concurrent private placement of warrants. The company will sell 3.625 million common shares at $0.795 and issue 3.625 million warrants at $0.005 each, exercisable at $0.84. Proceeds will support general corporate uses, including R&D and working capital, with Aegis Capital as placement agent.

Dyadic International (NASDAQ: DYAI) entered into agreements on Aug. 13, 2026 for a registered direct offering and concurrent private placement. It will sell 3,625,000 shares at $0.795/share and issue warrants to buy 3,625,000 shares with a $0.84 exercise price. Gross proceeds are expected at about $2.9 million, before expenses, for general corporate purposes.

DYADIC INTERNATIONAL INC (DYAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement JUPITER, FLA., August 13, 2026 -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company

DYADIC INTERNATIONAL INC (DYAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DYADIC ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS ACCELERATING COMMERCIALIZATION MOMENTUM ACROSS KEY BUSINESS AREAS Dyadic to host earnings call on August 12 at 5:00 pm ET JUPITER, FL — August 12, 2026 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, o

Dyadic International said it developed stable C1 cell line pools and produced two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens from plasmids in about 15 days. The antigens were delivered to Fondazione Biotecnopolo di Siena and Scripps Research for preclinical evaluation for a potential non-mRNA vaccine. Dyadic also cited prior C1 antibody titers above 12 g/L in seven days.

Dyadic International Inc. (DYAI) said it has regained compliance with Nasdaq Capital Market listing rules after a prior Nasdaq notice citing violations of Rules 5550(a)(2) and 5550(b). According to the latest Nasdaq notification, its common stock will continue trading on Nasdaq. DYAI closed Friday at $1.19, down 1.65%.

Francisco Trust under agreement dated February 28, 1996 sold 95,392 shares of DYADIC INTERNATIONAL INC (DYAI) at an average of $1.31 ($1.21–$1.33, $0.12M total) across 3 trades over 2026-07-22 to 2026-07-24.

Dyadic International, Inc. (Nasdaq: DYAI) said Nasdaq confirmed it has regained compliance with listing rules 5550(a)(2) and 5550(b). The company’s common stock will continue trading on the Nasdaq Capital Market. Dyadic attributed the resolution to Nasdaq’s continued listing review and said it will focus on its protein platforms and collaborations.